Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

CODX Stock  USD 0.73  0.03  3.95%   
Slightly above 61% of Co Diagnostics' investor base is looking to short. The analysis of overall sentiment of trading Co Diagnostics stock suggests that many investors are alarmed at this time. Co Diagnostics' investing sentiment can be driven by a variety of factors including economic data, Co Diagnostics' earnings reports, geopolitical events, and overall market trends.
  
Co-Diagnostics, Inc. , a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

Read at finance.yahoo.com
Yahoo News
  

Co Diagnostics Fundamental Analysis

We analyze Co Diagnostics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Co Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Co Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Liabilities

Current Liabilities Comparative Analysis

Co Diagnostics is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Co Diagnostics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Co Diagnostics stock to make a market-neutral strategy. Peer analysis of Co Diagnostics could also be used in its relative valuation, which is a method of valuing Co Diagnostics by comparing valuation metrics with similar companies.

Peers

Co Diagnostics Related Equities

HSCSHeart Test   11.99   
0%
100.0%
VVOSVivos Therapeutics   6.87   
0%
57.0%
MOVEMovano   6.20   
0%
51.0%
CLPTClearpoint Neuro   6.07   
0%
50.0%
TIVCTivic Health   5.00   
0%
41.0%
SENSSenseonics Holdings   4.55   
0%
37.0%
BMRABiomerica   3.70   
0%
30.0%
NPCENeuropace   3.50   
0%
29.0%
CVRXCVRx   3.33   
0%
27.0%
INGNInogen   2.05   
0%
17.0%
BBLGBone Biologics   1.94   
0%
16.0%
NURONeuroMetrix   1.56   
0%
13.0%
SRDXSurModics   0.40   
3.0%
0%
RSLSReShape Lifesciences   0.90   
7.0%
0%
BJDXBluejay Diagnostics   1.54   
12.0%
0%
NVNOEnVVeno Medical   1.58   
13.0%
0%
IINNInspira Technologies   4.30   
35.0%
0%
NAOVNanoVibronix   4.92   
41.0%
0%
RPIDRapid Micro   10.00   
83.0%
0%

Additional Tools for CODX Stock Analysis

When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.